Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-11-24 M&A Activity
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Selvita to acquire Fidelta from Galapagos
M&A Activity Classification · 99% confidence The document is a press release dated November 23, 2020, announcing that Selvita S.A. will acquire Fidelta d.o.o. from Galapagos NV. This type of announcement, detailing a significant corporate transaction (Merger & Acquisition activity), is typically classified under the M&A Activity category (TAR). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA). The content focuses entirely on the terms, rationale, and impact of the acquisition.
2020-11-24 English
Selvita to acquire Fidelta from Galapagos
M&A Activity Classification · 99% confidence The document is a press release dated November 23, 2020, announcing that Selvita is acquiring Fidelta from Galapagos for €31.2M. It details the strategic rationale, financial impact (doubling Selvita's revenue), and includes quotes from the CEOs of both companies. This type of announcement, detailing a significant corporate transaction (Merger/Acquisition), aligns best with the 'M&A Activity' category (TAR). It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a takeover proposal/agreement.
2020-11-24 Dutch
6-K Filing
Regulatory Filings
2020-11-24 English
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Earnings Release Classification · 85% confidence The document is a press release dated November 9, 2020, announcing that the first patient has been dosed in a Phase 1b clinical trial for a compound named GLPG3667 for psoriasis. It details the trial design (randomized, double-blind, placebo-controlled), endpoints (PASI score), and future plans (Phase 2 studies). This type of announcement, detailing clinical trial progress and pipeline updates, is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it focuses on specific clinical trial progress and pipeline news rather than comprehensive financial results (like a 10-K or IR) or management changes (MANG), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure and content—a headline announcement of a key operational milestone (dosing the first patient) with forward-looking statements and contact information—it strongly aligns with the function of an Earnings Release (ER) which often contains operational updates alongside financial reporting, or a general announcement. However, since it is not explicitly stating quarterly/periodical financial results (ER definition), and it is a specific operational update, it is most accurately classified as a general announcement that doesn't fit the other specific categories. In the context of financial reporting databases, press releases detailing clinical trial milestones are often categorized under the closest operational announcement type. Since it is a specific operational update and not a formal report (like 10-K or IR), and it's not a dividend or management change, the best fit among the provided options that covers operational news is ER, or RNS as a fallback. Given the focus on pipeline progress, it is a key investor communication. I will classify it as an Earnings Release (ER) as these often include operational milestones, but recognizing it's not a pure financial summary. If it were purely a clinical trial update without any context of a reporting period, RNS might be considered, but ER is often used for major operational news releases. Q4 2020
2020-11-10 English
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV dated November 9, 2020, announcing that the first patient has been dosed in a Phase 1b study for their drug candidate GLPG3667 in psoriasis patients. It details the study design (double-blind, placebo-controlled), endpoints (PASI score), and future plans (Phase 2 studies in psoriatic arthritis and ulcerative colitis). This content—announcing clinical trial progress, safety updates, and pipeline development—is characteristic of an Earnings Release (ER) or a general press release related to operational updates. Since it focuses on the initial results/milestone of a clinical trial rather than a full financial period report (like 10-K or IR), and it is an announcement of operational progress, it fits best under the 'Earnings Release' category (ER) which often includes key operational highlights alongside financial results, or sometimes functions as a standalone operational update press release. Given the options, 'ER' is the closest fit for a major operational/clinical milestone announcement, although 'RNS' (Regulatory Filings) is a possibility if it were purely regulatory. However, the content is clearly an operational/clinical update press release, which frequently accompanies or substitutes for a formal ER in biotech. Since it is a specific announcement about a clinical milestone, and not a full financial report, ER is the most appropriate classification among the specific choices provided for operational news. Q4 2020
2020-11-10 English
6-K Filing
Regulatory Filings
2020-11-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.